Atria Investments LLC Grows Stake in Horizon Therapeutics Public Limited (NASDAQ:HZNP)

Atria Investments LLC raised its stake in Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating) by 5.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,312 shares of the biopharmaceutical company’s stock after purchasing an additional 507 shares during the quarter. Atria Investments LLC’s holdings in Horizon Therapeutics Public were worth $1,085,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Johnson Financial Group Inc. purchased a new position in Horizon Therapeutics Public in the fourth quarter valued at about $25,000. UMB Bank N A MO acquired a new stake in shares of Horizon Therapeutics Public during the fourth quarter valued at about $34,000. Covestor Ltd acquired a new stake in shares of Horizon Therapeutics Public during the fourth quarter valued at about $37,000. Citizens National Bank Trust Department acquired a new stake in shares of Horizon Therapeutics Public during the fourth quarter valued at about $38,000. Finally, Parallel Advisors LLC grew its stake in shares of Horizon Therapeutics Public by 65.9% during the first quarter. Parallel Advisors LLC now owns 408 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 162 shares in the last quarter. 88.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HZNP has been the subject of several recent analyst reports. Wells Fargo & Company restated a “buy” rating and set a $133.00 target price on shares of Horizon Therapeutics Public in a research note on Friday, April 8th. StockNews.com assumed coverage on Horizon Therapeutics Public in a research note on Thursday, March 31st. They set a “hold” rating for the company. UBS Group decreased their price target on Horizon Therapeutics Public from $139.00 to $137.00 and set a “buy” rating for the company in a research note on Tuesday, July 5th. SVB Leerink assumed coverage on Horizon Therapeutics Public in a research note on Monday, May 23rd. They issued a “market perform” rating and a $95.00 price target for the company. Finally, Oppenheimer reiterated a “buy” rating and issued a $140.00 price target on shares of Horizon Therapeutics Public in a research note on Friday, July 8th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $133.10.

Insider Activity

In related news, CEO Timothy P. Walbert sold 17,600 shares of the business’s stock in a transaction that occurred on Wednesday, May 11th. The stock was sold at an average price of $90.00, for a total transaction of $1,584,000.00. Following the sale, the chief executive officer now owns 460,549 shares of the company’s stock, valued at $41,449,410. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CEO Timothy P. Walbert sold 17,600 shares of the business’s stock in a transaction that occurred on Wednesday, May 11th. The stock was sold at an average price of $90.00, for a total transaction of $1,584,000.00. Following the sale, the chief executive officer now owns 460,549 shares of the company’s stock, valued at $41,449,410. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Timothy P. Walbert sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, May 20th. The stock was sold at an average price of $90.00, for a total value of $2,250,000.00. Following the sale, the chief executive officer now directly owns 460,549 shares in the company, valued at approximately $41,449,410. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 100,934 shares of company stock valued at $9,206,533. Insiders own 2.50% of the company’s stock.

Horizon Therapeutics Public Stock Performance

Shares of HZNP stock opened at $82.02 on Thursday. The business has a 50 day moving average of $85.07 and a two-hundred day moving average of $94.21. The company has a market cap of $18.86 billion, a P/E ratio of 22.47, a PEG ratio of 1.18 and a beta of 1.17. The company has a quick ratio of 3.30, a current ratio of 3.57 and a debt-to-equity ratio of 0.53. Horizon Therapeutics Public Limited has a 52 week low of $78.40 and a 52 week high of $120.54.

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) last released its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.15 by $0.19. The company had revenue of $885.25 million for the quarter, compared to analysts’ expectations of $866.39 million. Horizon Therapeutics Public had a return on equity of 32.08% and a net margin of 22.87%. The business’s revenue for the quarter was up 158.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 earnings per share. As a group, analysts anticipate that Horizon Therapeutics Public Limited will post 5.6 EPS for the current year.

Horizon Therapeutics Public Company Profile

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

See Also

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating).

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.